AN ACT TO BE KNOWN AS THE IBOGAINE DRUG DEVELOPMENT CLINICAL TRIAL ACT; TO AUTHORIZE THE ESTABLISHMENT OF A CONSORTIUM TO APPLY FOR SELECTION BY THE STATE DEPARTMENT OF HEALTH TO CONDUCT A DRUG DEVELOPMENT CLINICAL TRIAL WITH IBOGAINE AND SECURE THE UNITED STATES FOOD AND DRUG ADMINISTRATION'S (FDA) APPROVAL OF IBOGAINE AS A MEDICATION FOR THE TREATMENT OF OPIOID USE DISORDER, CO-OCCURRING SUBSTANCE USE DISORDER, AND ANY OTHER NEUROLOGICAL OR MENTAL HEALTH CONDITION FOR WHICH IBOGAINE DEMONSTRATES EFFICACY; TO REQUIRE THE CONSORTIUM TO SUBMIT TO THE DEPARTMENT A PROPOSAL FOR PURPOSES OF CONDUCTING AN IBOGAINE DRUG DEVELOPMENT CLINICAL TRIAL, AND SPECIFY WHAT THE PROPOSAL MUST INCLUDE; TO PROVIDE THAT AFTER SELECTING A CONSORTIUM, THE DEPARTMENT SHALL ENTER INTO AN INTERAGENCY CONTRACT WITH THE CONSORTIUM TO PROVIDE FUNDING TO IMPLEMENT THE CONSORTIUM'S PROPOSED IBOGAINE DRUG DEVELOPMENT CLINICAL TRIAL; TO SPECIFY WHAT THE INTERAGENCY CONTRACT MUST INCLUDE; TO PROVIDE THAT THE DEPARTMENT MAY NOT DISBURSE FUNDS TO OR FOR A SELECTED CONSORTIUM UNDER THE INTERAGENCY CONTRACT UNTIL THE CONSORTIUM RECEIVES AND THE DEPARTMENT VERIFIES THE RECEIPT OF MATCHING FUNDS FROM SOURCES OTHER THAN THE STATE; TO REQUIRE THE SELECTED CONSORTIUM TO ENTER INTO AN AGREEMENT WITH THE LEAD CONSORTIUM ESTABLISHED BY THE GOVERNMENT OF ANOTHER STATE THAT HAS SUBMITTED AN INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO THE FDA AND HAS REQUESTED A BREAKTHROUGH THERAPY DESIGNATION FOR IBOGAINE FROM THE FDA; TO REQUIRE THE SELECTED CONSORTIUM TO WORK WITH THE FDA TO COORDINATE THE DRUG DEVELOPMENT TRIAL IN MISSISSIPPI WITH IBOGAINE DRUG DEVELOPMENT TRIALS THAT ARE BEING CONDUCTED BY THE LEAD CONSORTIUM AND IN OTHER STATES; TO PROVIDE THAT ONLY AN INSTITUTION OF HIGHER LEARNING OR A HOSPITAL MAY SERVE AS A TRIAL SITE FOR CONDUCTING AN IBOGAINE DRUG DEVELOPMENT CLINICAL TRIAL; TO PROVIDE FOR ALLOCATION OF THE REVENUE ATTRIBUTABLE TO ALL INTELLECTUAL PROPERTY RIGHTS AND OTHER COMMERCIAL RIGHTS ARISING FROM THE DRUG DEVELOPMENT CLINICAL TRIAL CONDUCTED BY A CONSORTIUM DURING THE PERIOD FOR WHICH THE TRIAL IS FUNDED AND ANY FOLLOWING PERIOD OF COMMERCIALIZATION; TO PROVIDE THAT IF IBOGAINE IS APPROVED BY THE FDA TO TREAT A MEDICAL CONDITION, A PHYSICIAN WHO HAS PRESCRIBED IBOGAINE FOR A PATIENT SHALL SUPERVISE THE ADMINISTRATION OF IBOGAINE AT A HOSPITAL OR OTHER LICENSED HEALTH CARE FACILITY TO ENSURE THE PATIENT'S SAFETY WHILE THE PATIENT IS UNDER THE INFLUENCE OF IBOGAINE; AND FOR RELATED PURPOSES.
HB314 creates the Ibogaine Drug Development Clinical Trial Act, authorizing the Mississippi State Department of Health to select a consortium to design and carry out an ibogaine clinical trial aimed at obtaining FDA approval of ibogaine for opioid use disorder, co-occurring substance use disorder, and potentially other neurological or mental health conditions where efficacy is shown. The bill requires the consortium to include a drug developer, an institution of higher learning, and a hospital, and to submit a detailed proposal covering FDA strategy, trial design, patient screening, cardiac safety, aftercare, data integrity, provider training, access for uninsured patients, and plans to secure payer coverage after approval.
The department is directed to enter an interagency contract with the selected consortium and provide state funding only after matching non-state funds are verified. The bill also requires coordination with a lead consortium in another state that has filed an IND application and sought breakthrough therapy designation, and it limits trial sites to hospitals or institutions of higher learning. It further establishes reporting obligations to the department and Legislature, allows acceptance of gifts and grants, and sets a revenue-sharing framework for intellectual property and commercial rights arising from the trial, with at least 20% of related revenue paid to the state general fund.
If ibogaine is later approved by the FDA, the bill creates a supervised administration framework requiring a licensed Mississippi physician to oversee administration at a hospital or other licensed health care facility to protect patient safety while under the influence of ibogaine. The act also contemplates federal waivers or authorizations if needed before implementation, and it takes effect July 1, 2026.
The bill’s impact on state law is to create a new state-sponsored pathway for drug development research, funding, and commercialization tied to ibogaine, while also laying groundwork for future clinical administration rules if federal approval occurs. It affects the State Department of Health, public and private research partners, hospitals, universities, drug developers, insurers, and potentially Medicaid, Medicare, TRICARE, and uninsured patients if the treatment is approved and adopted. It also creates a state claim to a share of intellectual property and commercial revenue generated by the trial.
The overall sentiment appears strongly favorable, as reflected by overwhelming bipartisan passage in both chambers and concurrence on Senate amendments, with only a small number of dissenting votes. The main points of contention likely center on ibogaine’s safety, the appropriateness of state investment in an experimental therapy, the requirement for matching funds, and the state’s role in claiming commercial rights and future revenue from the research. The bill’s detailed safety, reporting, and federal-compliance provisions suggest an effort to address those concerns while advancing the trial.
HB314 adds a new statutory framework authorizing the State Department of Health to select and fund an ibogaine research consortium, subject to legislative appropriation and verified matching funds. It establishes requirements for consortium composition, proposal contents, trial-site eligibility, reporting, revenue allocation from intellectual property and commercialization, and a future physician-supervised administration model if FDA approval is obtained. The bill does not itself legalize ibogaine for general use, but it creates state-level infrastructure to pursue FDA approval and prepare for post-approval implementation.
The bill appears to have broad legislative support, passing the House 110-1, the Senate 51-1 on amended versions, and the House again 115-3 to concur in Senate amendments. That voting pattern suggests strong interest in advancing ibogaine research as a potential response to opioid and substance use disorders, with limited opposition. No committee transcript was provided, so the available record shows support through votes rather than recorded debate.
Likely areas of concern include ibogaine’s clinical safety profile, especially cardiac risks, the use of public funds for an investigational treatment, and the requirement that state funding be matched by non-state sources before disbursement. There may also be debate over the state’s claim to at least 20% of intellectual property and commercialization revenue, as well as the bill’s reliance on federal approvals, waivers, and coordination with an out-of-state lead consortium. Supporters appear to prioritize innovation, addiction treatment options, and economic development; skeptics likely focus on medical uncertainty, regulatory risk, and fiscal exposure.